Skip to main content

Table 1 US FDA-Approved BCR-ABL1 TKIs

From: Biomarkers for determining the prognosis in chronic myelogenous leukemia

Name Year approved Indications in CML
Imatinib 2001 CP, AP, or BC after failure of interferon therapy
2003 Newly diagnosed CP
Dasatinib 2006 CP, AP, or BC after resistance to or intolerance of imatinib
2010 Newly diagnosed CP
Nilotinib 2007 CP or AP after resistance to or intolerance of imatinib
2010 Newly diagnosed CP
Bosutinib 2012 CP, AP, or BC after resistance to or intolerance of prior therapy
Ponatinib 2012 CP, AP, or BC after resistance to or intolerance of prior TKI therapy
  1. AP accelerated phase, BC blast crisis, CML chronic myelogenous leukemia, CP chronic phase, FDA Food and Drug Administration, TKI tyrosine kinase inhibitor, US United States.